Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Refoxy Pharma

Request full access

Refoxy is a Pharmaceutical company discovering medicines to treat age-related diseases and extend the years of healthy living

Cologne, GermanyFounded 2020Biotech & Life Sciences

About Refoxy Pharma

Refoxy Pharma is a pioneering pharmaceutical company focused on discovering and developing medicines to treat age-related diseases and extend healthy living years. The company operates in the biotechnology and pharmaceutical market, targeting a growing demographic of aging populations worldwide. Refoxy's primary clients include healthcare providers, medical researchers, and patients suffering from age-related conditions.

The core of Refoxy's innovation lies in its research on FOXO proteins, a type of protein known as transcription factors. These proteins bind to specific DNA sequences and control the expression of genes, which can influence various biological processes such as stress resistance, metabolism, and longevity. By enhancing the function of FOXO proteins, Refoxy aims to develop therapeutic medicines that can repair, restore, and rejuvenate the body's natural functions, thereby improving healthspan—the period of life spent in good health.

Refoxy's business model revolves around extensive scientific research and development (R&D) to create novel drugs. The company invests heavily in understanding the genetic and environmental factors that influence aging. By leveraging this knowledge, Refoxy designs interventions that can modulate these factors to promote longer, healthier lives. The company generates revenue through the sale of its pharmaceutical products, licensing its technologies to other biotech firms, and forming strategic partnerships with healthcare organizations.

In summary, Refoxy Pharma is at the forefront of age-related disease treatment, using cutting-edge genetic research to develop medicines that enhance longevity and improve quality of life.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
79.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Biotech and Pharma, EIT Health, Longevity, proteomics, DT and LS, KoelnBusiness, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDOther financing Dec 2024 $10M $40M HTGF · NRW.BANK · Apollo Health Ventures · Boehringer Ingelheim Venture Fund ↗
SUPPORT PROGRAMOther financing Jan 2023 $0 — EIT Health —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Refoxy Pharma website traffic

Latest recorded traffic for Refoxy Pharma is 980 monthly website visits, up 58.1% over the last three months. Refoxy Pharma's team grew 9.1% over the past year.

Latest monthly visits980 3-month web change+58.1% 1-year team growth+9.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Refoxy Pharma in the Cologne ecosystem

Live from Dealroom

The Refoxy Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Boehringer Ingelheim Venture Fund
  • HTGF
  • NRW.BANK
  • Apollo Health Ventures

Other known investors1 additional known investor

  • EIT Health
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Refoxy Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.